Investigação dos Mecanismos Cerebrais Envolvidos no Mecanismo de Continência Urinária Associado ao Envelhecimento
Urge urinary incontinence (UUI) is a common problem in older people which vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will characterize brain control of the bladder in young and old continent individuals and age-matched incontinent counterparts. This will expand the investigators current knowledge of how the brain controls the bladder, how that control changes with age and disease, and suggest new targets to guide development of better treatment.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Current data suggest that bladder control comprises 3 cerebral circuits that maintain continence by suppressing the voiding reflex in the midbrain. In the UUI phenotype that responded to BFB (Biofeedback assisted pelvic floor muscle therapy), the mechanism involved enhancing deactivation of the first brain circuit (medial prefrontal cortex, mPFC) which resulted in less activation of the second circuit (which includes the midcingulate cortex). In the phenotype that was resistant to BFB, no brain changes were seen. Although the investigators have an emerging picture of the brain's role in UUI, the investigators have only rudimentary understanding of what is 'normal', i.e. how the brain normally controls the bladder. Moreover, the investigators do not know whether this control mechanism is the same across the lifespan, or whether it changes owing to the impact of aging. Thus, the investigators aims are to characterize the brain's normal role in bladder control in both young and old people, to determine the changes in brain structure and function that lead to bladder control failure (UUI), and to examine how such changes differ between young and old individuals. To address the aims, the investigators will utilize detailed neuroimaging to evaluate 80 asymptomatic women and 80 women with UUI, each group divided into young (18-45) and old (65+ years) individuals. The study will enable the investigators to define the brain's key structures, functional activity, and mechanisms involved in normal bladder control, and to identify the differences in these elements among those with UUI, both young and old.
By elucidating the mechanisms that mediate the brain's control (and loss of control) of bladder function, the proposed study should enhance the investigators working model, deepen the understanding of the impact of aging, and identify better targets for the treatment of UUI. It may thereby enable scientists to develop novel and more effective new therapies based on the revolution in neuroscience-and more hope for UUI sufferers.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- University of Pittsburgh
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- 'Old' (community-dwelling, mentally and functionally intact ambulatory women aged 65+ years) or 'Young' (equivalent women aged 18-45)
- 'Wet' (those who meet the International Continence Society definition of urgency urinary incontinence (urinary leakage accompanied by a sudden, strong urge to void which is difficult to defer) >5 times per week, for 3 months despite treatment for reversible causes (e.g., Urinary tract infection) and confirmed by a mean of one episode per day of UUI on 3-day bladder diary) or 'Dry' (women without current or past UUI or other lower urinary tract symptoms.) Infrequent stress incontinence of a small amount is acceptable.
- Urge-predominant mixed incontinence is acceptable provided the subject is able to differentiate between stress incontinence (SUI - leakage that coincides instantaneously with cough, laugh, exercise) and urgency incontinence, i.e., leakage accompanied by a sudden strong urge to void that is difficult to defer.
- Those with current or previous use of anticholinergic/beta-3 agonist medications will be considered for the study if they are willing to go through a washout period of at least 4 weeks of duration.
Exclusion Criteria:
Dry Groups
- Current or prior treatment for UUI
- Leakage on bladder diary not ascribed to minimal SUI (see bullet above)
All Groups: 'Wet' or 'Dry'; 'Young' or 'Old'
-
Cognitive impairment:
- MoCA<26
- inability to perform a voiding diary/pad test
- inability to reliably take daily medication
- inability to comply with fMRI testing
-
Impaired mobility
o Timed up and go test ≥ 12 secs
-
Medical instability:
- severe uncontrolled hypertension >180mmHg systolic or >100mmHg diastolic
- potential major changes in medical management over the course of the study period (i.e. upcoming surgery/treatment)
- frailty according to the Fried criteria
-
MRI incompatibility:
- contraindicated metal implants
- claustrophobia
- unidentified/untested compatibility of metal implants
-
Medication incompatibility:
- allergy to study medication (all prophylactic antibiotic choices)
- interaction of prophylactic antibiotic choices with current medications
- expected change in medication during the study
-
Neurological conditions:
- spinal cord injury;
- multiple sclerosis
- clinically apparent lesions (e.g. lacunae associated with stroke)
- prior stroke
- Parkinson's Disease/ALS/MSA
- any clinically apparent neurological condition
-
Lower urinary tract comorbidities/treatment:
- history of pelvic irradiation
- bladder or advanced uterine cancer
- possible urethral obstruction (advanced prolapse [POP-Q>II] or Qmax<12 ml/s on free flow)
- urinary retention (PVR >200 ml)
- Interstitial Cystitis/Bladder Pain Syndrome
- artificial sphincter implant
- Botox treatment for UUI within 1 year
- Neuromodulation treatment for UUI
-
Other comorbidities:
- uncontrolled depression (PHQ-9 ≥10)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Brain functional MRI with simplified urodynamics
Females with urgency urinary incontinence |
Structural: MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans. Functional: With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC
Prazo: Baseline
|
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined mPFC (medial prefrontal cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition. |
Baseline
|
|
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula
Prazo: Baseline
|
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined insula region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition. |
Baseline
|
|
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC
Prazo: Baseline
|
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined dACC (dorsal anterior cingulate cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition. |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Becky Clarkson, PhD, University of Pittsburgh
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Distúrbios da micção
- Sintomas do Trato Urinário Inferior
- Manifestações Urológicas
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Incontinencia urinaria
Outros números de identificação do estudo
Outros números de identificação do estudo
- STUDY20080217
- R01AG065288 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
All of the individual participant data collected during the trial, after de-identification may be shared with other researchers.
Prazo de Compartilhamento de IPD
Following publication, no end date
Critérios de acesso de compartilhamento IPD
Any purpose
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .